- Home
- OGI vs CHRS Comparison
OGI vs CHRS Comparison
Compare OGI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- CHRS
- Stock Information
- Founded
- OGI 2013
- CHRS 2010
- Country
- OGI Canada
- CHRS United States
- Employees
- OGI N/A
- CHRS N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGI Health Care
- CHRS Health Care
- Exchange
- OGI Nasdaq
- CHRS Nasdaq
- Market Cap
- OGI 234.5M
- CHRS 194.1M
- IPO Year
- OGI N/A
- CHRS 2014
- Fundamental
- Price
- OGI $1.77
- CHRS $1.66
- Analyst Decision
- OGI
- CHRS Strong Buy
- Analyst Count
- OGI 0
- CHRS 4
- Target Price
- OGI N/A
- CHRS $4.51
- AVG Volume (30 Days)
- OGI 863.0K
- CHRS 1.0M
- Earning Date
- OGI 08-13-2025
- CHRS 11-10-2025
- Dividend Yield
- OGI N/A
- CHRS N/A
- EPS Growth
- OGI N/A
- CHRS N/A
- EPS
- OGI 0.05
- CHRS 1.55
- Revenue
- OGI $164,107,753.00
- CHRS $272,209,000.00
- Revenue This Year
- OGI $59.31
- CHRS N/A
- Revenue Next Year
- OGI $15.12
- CHRS $109.48
- P/E Ratio
- OGI $41.54
- CHRS $3.23
- Revenue Growth
- OGI 50.01
- CHRS 52.33
- 52 Week Low
- OGI $0.85
- CHRS $0.66
- 52 Week High
- OGI $2.08
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- OGI 46.32
- CHRS 53.13
- Support Level
- OGI $1.67
- CHRS $1.64
- Resistance Level
- OGI $2.05
- CHRS $1.82
- Average True Range (ATR)
- OGI 0.09
- CHRS 0.10
- MACD
- OGI -0.03
- CHRS -0.03
- Stochastic Oscillator
- OGI 20.41
- CHRS 11.54
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.